Waters Corporation $WAT Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC cut its stake in Waters Corporation (NYSE:WAT) by 1.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 198,673 shares of the medical instruments supplier’s stock after selling 3,519 shares during the quarter. Natixis Advisors LLC’s holdings in Waters were worth $59,564,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Root Financial Partners LLC acquired a new stake in shares of Waters during the 3rd quarter worth approximately $26,000. ANTIPODES PARTNERS Ltd acquired a new stake in Waters during the third quarter valued at $26,000. Hantz Financial Services Inc. increased its holdings in Waters by 115.4% in the third quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 60 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new position in shares of Waters in the second quarter worth about $53,000. Finally, Versant Capital Management Inc boosted its stake in shares of Waters by 510.3% during the 3rd quarter. Versant Capital Management Inc now owns 177 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 148 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Waters Stock Up 1.2%

WAT stock opened at $306.09 on Tuesday. Waters Corporation has a 52 week low of $275.05 and a 52 week high of $414.15. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37. The firm has a 50-day simple moving average of $359.85 and a 200-day simple moving average of $351.76. The stock has a market capitalization of $30.03 billion, a P/E ratio of 28.42, a P/E/G ratio of 2.08 and a beta of 1.20.

Waters (NYSE:WAT) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The firm had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. During the same period last year, the company posted $4.10 EPS. Waters’s quarterly revenue was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Equities analysts forecast that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

WAT has been the topic of a number of analyst reports. Wolfe Research upgraded Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 target price on the stock in a research report on Wednesday, December 10th. Evercore started coverage on Waters in a report on Tuesday, February 10th. They issued a “hold” rating and a $360.00 price target for the company. Wells Fargo & Company dropped their price objective on Waters from $415.00 to $355.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 11th. Barclays initiated coverage on Waters in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $400.00 price objective for the company. Finally, Guggenheim reaffirmed a “buy” rating and set a $440.00 target price on shares of Waters in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Waters presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.84.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.